172 related articles for article (PubMed ID: 37059384)
1. Investigating fatty liver disease-associated adverse outcome pathways of perfluorooctane sulfonate using a systems toxicology approach.
Kim M; Kim SH; Choi JY; Park YJ
Food Chem Toxicol; 2023 Jun; 176():113781. PubMed ID: 37059384
[TBL] [Abstract][Full Text] [Related]
2. A quantitative weight-of-evidence method for confidence assessment of adverse outcome pathway networks: A case study on chemical-induced liver steatosis.
Verhoeven A; van Ertvelde J; Boeckmans J; Gatzios A; Jover R; Lindeman B; Lopez-Soop G; Rodrigues RM; Rapisarda A; Sanz-Serrano J; Stinckens M; Sepehri S; Teunis M; Vinken M; Jiang J; Vanhaecke T
Toxicology; 2024 Jun; 505():153814. PubMed ID: 38677583
[TBL] [Abstract][Full Text] [Related]
3. Linking nanomaterial-induced mitochondrial dysfunction to existing adverse outcome pathways for chemicals.
Murugadoss S; Vinković Vrček I; Schaffert A; Paparella M; Pem B; Sosnowska A; Stępnik M; Martens M; Willighagen EL; Puzyn T; Roxana Cimpan M; Lemaire F; Mertens B; Dusinska M; Fessard V; Hoet PH
ALTEX; 2024 Jan; 41(1):76-90. PubMed ID: 37606097
[TBL] [Abstract][Full Text] [Related]
4. AOP-helpFinder webserver: a tool for comprehensive analysis of the literature to support adverse outcome pathways development.
Jornod F; Jaylet T; Blaha L; Sarigiannis D; Tamisier L; Audouze K
Bioinformatics; 2022 Jan; 38(4):1173-1175. PubMed ID: 34718414
[TBL] [Abstract][Full Text] [Related]
5. An integrative systems biology strategy to support the development of adverse outcome pathways (AOPs): a case study on radiation-induced microcephaly.
Jaylet T; Quintens R; Armant O; Audouze K
Front Cell Dev Biol; 2023; 11():1197204. PubMed ID: 37427375
[TBL] [Abstract][Full Text] [Related]
6. A case example of a radiation-relevant adverse outcome pathway to lung cancer.
Chauhan V; Sherman S; Said Z; Yauk CL; Stainforth R
Int J Radiat Biol; 2021; 97(1):68-84. PubMed ID: 31846388
[TBL] [Abstract][Full Text] [Related]
7. An integrative data-centric approach to derivation and characterization of an adverse outcome pathway network for cadmium-induced toxicity.
Sahoo AK; Chivukula N; Ramesh K; Singha J; Marigoudar SR; Sharma KV; Samal A
Sci Total Environ; 2024 Apr; 920():170968. PubMed ID: 38367714
[TBL] [Abstract][Full Text] [Related]
8. Challenges in the quantification approach to a radiation relevant adverse outcome pathway for lung cancer.
Stainforth R; Schuemann J; McNamara AL; Wilkins RC; Chauhan V
Int J Radiat Biol; 2021; 97(1):85-101. PubMed ID: 32909875
[TBL] [Abstract][Full Text] [Related]
9. [Molecular Pathway and AOP Development Using Gene Network Analysis].
Tanabe S; Hirose A; Whelan M; Yamada T
Yakugaku Zasshi; 2020; 140(4):485-489. PubMed ID: 32238629
[TBL] [Abstract][Full Text] [Related]
10. A toxicity pathway-oriented approach to develop adverse outcome pathway: AHR activation as a case study.
Jin Y; Feng M; Ma W; Wei Y; Qi G; Luo J; Xu L; Li X; Li C; Wang Y; Li D; Chen J; Zhao Y; Hou Y; Zhao Q; Jiang L; Xie M; Zheng Y; Yu D
Environ Pollut; 2021 Jan; 268(Pt B):115733. PubMed ID: 33011576
[TBL] [Abstract][Full Text] [Related]
11. Defining the Biologically Plausible Taxonomic Domain of Applicability of an Adverse Outcome Pathway: A Case Study Linking Nicotinic Acetylcholine Receptor Activation to Colony Death.
Jensen MA; Blatz DJ; LaLone CA
Environ Toxicol Chem; 2023 Jan; 42(1):71-87. PubMed ID: 36263952
[TBL] [Abstract][Full Text] [Related]
12. AOP-helpFinder 2.0: Integration of an event-event searches module.
Jaylet T; Coustillet T; Jornod F; Margaritte-Jeannin P; Audouze K
Environ Int; 2023 Jul; 177():108017. PubMed ID: 37295163
[TBL] [Abstract][Full Text] [Related]
13. Adverse outcome pathways and linkages to transcriptomic effects relevant to ionizing radiation injury.
Yu J; Tu W; Payne A; Rudyk C; Cuadros Sanchez S; Khilji S; Kumarathasan P; Subedi S; Haley B; Wong A; Anghel C; Wang Y; Chauhan V
Int J Radiat Biol; 2022; 98(12):1789-1801. PubMed ID: 35939063
[TBL] [Abstract][Full Text] [Related]
14. The adverse outcome pathway for rodent liver tumor promotion by sustained activation of the aryl hydrocarbon receptor.
Becker RA; Patlewicz G; Simon TW; Rowlands JC; Budinsky RA
Regul Toxicol Pharmacol; 2015 Oct; 73(1):172-90. PubMed ID: 26145830
[TBL] [Abstract][Full Text] [Related]
15. A strategy towards the generation of testable adverse outcome pathways for nanomaterials.
Murugadoss S; Vinković Vrček I; Pem B; Jagiello K; Judzinska B; Sosnowska A; Martens M; Willighagen EL; Puzyn T; Dusinska M; Cimpan MR; Fessard V; Hoet PH
ALTEX; 2021; 38(4):580-594. PubMed ID: 34008034
[TBL] [Abstract][Full Text] [Related]
16. Development of an adverse outcome pathway for chemically induced hepatocellular carcinoma: case study of AFB1, a human carcinogen with a mutagenic mode of action.
Moore MM; Schoeny RS; Becker RA; White K; Pottenger LH
Crit Rev Toxicol; 2018 Apr; 48(4):312-337. PubMed ID: 29431554
[TBL] [Abstract][Full Text] [Related]
17. Mapping DEHP to the adverse outcome pathway network for human female reproductive toxicity.
Pogrmic-Majkic K; Samardzija Nenadov D; Tesic B; Fa Nedeljkovic S; Kokai D; Stanic B; Andric N
Arch Toxicol; 2022 Oct; 96(10):2799-2813. PubMed ID: 35790550
[TBL] [Abstract][Full Text] [Related]
18. Integrate mechanistic evidence from new approach methodologies (NAMs) into a read-across assessment to characterise trends in shared mode of action.
Escher SE; Aguayo-Orozco A; Benfenati E; Bitsch A; Braunbeck T; Brotzmann K; Bois F; van der Burg B; Castel J; Exner T; Gadaleta D; Gardner I; Goldmann D; Hatley O; Golbamaki N; Graepel R; Jennings P; Limonciel A; Long A; Maclennan R; Mombelli E; Norinder U; Jain S; Capinha LS; Taboureau OT; Tolosa L; Vrijenhoek NG; van Vugt-Lussenburg BMA; Walker P; van de Water B; Wehr M; White A; Zdrazil B; Fisher C
Toxicol In Vitro; 2022 Mar; 79():105269. PubMed ID: 34757180
[TBL] [Abstract][Full Text] [Related]
19. An Adverse Outcome Pathway (AOP) for forestomach tumors induced by non-genotoxic initiating events.
Proctor DM; Suh M; Chappell G; Borghoff SJ; Thompson CM; Wiench K; Finch L; Ellis-Hutchings R
Regul Toxicol Pharmacol; 2018 Jul; 96():30-40. PubMed ID: 29684431
[TBL] [Abstract][Full Text] [Related]
20. Adverse outcome pathway (AOP) development I: strategies and principles.
Villeneuve DL; Crump D; Garcia-Reyero N; Hecker M; Hutchinson TH; LaLone CA; Landesmann B; Lettieri T; Munn S; Nepelska M; Ottinger MA; Vergauwen L; Whelan M
Toxicol Sci; 2014 Dec; 142(2):312-20. PubMed ID: 25466378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
